We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The first U.S. COVID-19 vaccinations are to be given today using Pfizer/BioNTech’s vaccine, following the announcement late Friday that the FDA had granted the first emergency clearance for a coronavirus vaccine, a pivotal and unprecedented moment in the battle against the pandemic. Read More
UX701 is currently in late preclinical development, and the company expects to file an Investigational New Drug application before the year ends. Read More
Even in the midst of the COVID-19 pandemic, not all vaccine news has to do with the coronavirus: Pfizer said this week that the FDA has accepted for priority review a biologics license application (BLA) the company filed for its vaccine against a form of streptococcus that can lead to fatal infections. Read More
Approval was supported by a phase 3 study enrolling 125 HAE patients, with attacks reduced by 87 percent vs. placebo when administered biweekly at a 300-mg dosage. Read More
The agency granted the designation based on initial data from patients enrolled in the phase 1 and 2 portions of its TRIDENT-1 study, the company says. Read More